Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

91.19 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,056
Open 91.19
Bid (Size) 90.86 (400)
Ask (Size) 91.74 (100)
Prev. Close 91.19
Today's Range 91.19 - 91.19
52wk Range 79.52 - 124.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioNTech Q2 Earnings Call Highlights ↗
BioNTech (NASDAQ:BNTX) reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year... 
Via MarketBeat
Topics Earnings
BioNTech (NASDAQ:BNTX) Falls After Q2 Revenue Miss and Revised Full-Year Guidance ↗
Via Chartmill

Performance

YTD
-5.7%
-5.7%
1 Month
-3.3%
-3.3%
3 Month
-2.0%
-2.0%
6 Month
-13.6%
-13.6%
1 Year
-18.1%
-18.1%

More News

Read More
News headline image
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
From BioNTech SE
Via GlobeNewswire
BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides ↗
Via Chartmill
News headline image
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
News headline image
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring ↗
Via The Motley Fool
News headline image
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
From BioNTech SE
Via GlobeNewswire
News headline image
Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock ↗
Via The Motley Fool
Topics ETFs
News headline image
2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Biotech Stocks Worth Buying Before Their Potential Buyouts ↗
Via The Motley Fool
News headline image
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM ↗
Via MarketBeat
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Via The Motley Fool
News headline image
Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
BioNTech Announces New ADS Repurchase Program
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
From BioNTech SE
Via GlobeNewswire
News headline image
2 Healthcare Stocks to Buy and 1 to Approach With Caution ↗
Via The Motley Fool
News headline image
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
Via Finterra
Topics Initial Public Offering
News headline image
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
From BioNTech SE
Via GlobeNewswire

Frequently Asked Questions

Is BioNTech SE - American Depositary Shares publicly traded?
Yes, BioNTech SE - American Depositary Shares is publicly traded.
What exchange does BioNTech SE - American Depositary Shares trade on?
BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BioNTech SE - American Depositary Shares?
The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market
What is the current price of BioNTech SE - American Depositary Shares?
The current price of BioNTech SE - American Depositary Shares is 91.19
When was BioNTech SE - American Depositary Shares last traded?
The last trade of BioNTech SE - American Depositary Shares was at 08/06/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.